In-vitro Assays for Antimicrobial Assessment

Kurhekar, Jaya Vikas; Tupas, Genevieve D.; Otero, Maria Catherine B.

doi:10.1007/978-981-13-6920-9_15

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various bioassays can be used to assess the antibacterial potential of extracts or single compounds [18]. The most widespread include microdilution techniques and agar diffusion methods, but bioautography on thin-layer chromatography, flow or image cytometry, or bioluminescence or biofilm assays can be also applied.…”

Section: Antibacterial Bioassaysmentioning

confidence: 99%

“…Spiromentin C (3), a p-terphenyl quinone purified from the velvet roll-rim Tapinella atrotomentosa (Tapinellaceae, Basidiomycetes), exerts an interesting inhibition against ESBL-producing E. coli, as well as against multiresistant A. baumannii, with MIC values of 10 and 20 µg/mL, respectively [27]. Even though A. baumannii is defined as sensitive to conventional antibiotics for MIC below 8 µg/mL [18], this result is nevertheless encouraging, as ▶ Table 4 Compounds isolated from mushrooms with antibacterial activity against Acinetobacter baumannii.…”

Section: Quinone Derivativesmentioning

confidence: 99%

See 1 more Smart Citation

Antibacterial Compounds from Mushrooms: A Lead to Fight ESKAPEE Pathogenic Bacteria?

et al. 2020

View full text Add to dashboard Cite

Infectious diseases are among the greatest threats to global health in the 21st century, and one critical concern is due to antibiotic resistance developed by an increasing number of bacterial strains. New resistance mechanisms are emerging with many infections becoming more and more difficult if not impossible to treat. This growing phenomenon not only is associated with increased mortality but also with longer hospital stays and higher medical costs. For these reasons, there is an urgent need to find new antibiotics targeting pathogenic microorganisms such as ESKAPEE bacteria. Most of currently approved antibiotics are derived from microorganisms, but higher fungi could constitute an alternative and remarkable reservoir of anti-infectious compounds. For instance, pleuromutilins constitute the first class of antibiotics derived from mushrooms. However, macromycetes still represent a largely unexplored source. Publications reporting the antibacterial potential of mushroom extracts are emerging, but few purified compounds have been evaluated for their bioactivity on pathogenic bacterial strains. Therefore, the aim of this review is to compile up-to-date data about natural products isolated from fruiting body fungi, which significantly inhibit the growth of ESKAPEE pathogenic bacteria. When available, data regarding modes of action and cytotoxicity, mandatory when considering a possible drug development, have been discussed in order to highlight the most promising compounds.

show abstract

Section: Antibacterial Bioassaysmentioning

confidence: 99%

Section: Quinone Derivativesmentioning

confidence: 99%